Clinical Trials · NCT00444639
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Ipsen
- Enrollment
- 25
- Start date
- Feb 2007
- Locations
- 15 sites, Netherlands
- Primary endpoint
- Percentage of patients achieving a plasma testosterone level ≤ 50 ng/dl (1,7 nmol/l).